Molecular imaging for non-invasive assessment of angiogenesisis is of great interest for clinicians because of the wide-spread application of anti-angiogenic cancer therapeutics. Besides, many other interventions that involve the change of blood vessel/tumor microenvironment would also benefit from such imaging strategies. Of the imaging techniques that target angiogenesis, radiolabeled Arg-Gly-Asp (RGD) peptides have been a major focus because of their high affinity and selectivity for integrin α v β 3 --one of the most extensively examined target of angiogenesis. Since the level of integrin α v β 3 expression has been established as a surrogate marker of angiogenic activity, imaging α v β 3 expression can potentially be used as an early indicator of effectiveness of antiangiogenic therapy at the molecular level. In this review, we summarize RGD-based PET tracers that have already been used in clinical trials and intercompared them in terms of radiosynthesis, dosimetry, pharmacokinetics and clinical applications. A perspective of their future use in the clinic is also provided.
Introduction
Tumor angiogenesis is the process of forming new blood vessels from preexisting vasculatures, which has been well recognized as an essential hallmark for tumor growth, invasion and metastasis [1] . Without the neovasculature to transport oxygen and nutrients, solid tumors cannot grow beyond 1-2 mm in size [2] . Once vascularized, the tumor begins to grow rapidly. The angiogenic process depends on migration and invasion of vascular endothelial cells and is mainly regulated by vascular endothelial growth factor receptors (VEGFRs) and cell adhesion receptor integrins [3] .
Integrins, which contain two noncovalently bound transmembrane subunits (α and β subunits), are the bridges for cell-cell and cell-extracellular matrix (ECM) interactions [4] . Integrins play very important roles in tumor angiogenesis and metastasis [5] . Several integrins, especially integrin αvβ3, are significantly up-regulated on activated endothelial cells during angiogenesis but not on quiescent endothelial cells [6, 7] . Therefore, integrin α v β 3 represents a potential molecular marker for angiogenesis during imaging and therapy [4] .
Majority of integrin-targeted imaging tracers are based on the tripeptide Arg-Gly-Asp (RGD) acid sequence because of its high affinity and specificity for integrin αvβ3. These tracers were developed for various imaging strategies, including positron emission tomography (PET), single photon emission computed tomography (SPECT), molecular magnetic resonance imaging (mMRI), optical fluorescence, optical bioluminescence, photoacoustic, and targeted contrast-enhanced ultrasound [8] [9] [10] [11] [12] [13] . Although the spatial and temporal resolutions of PET may not be as impressive as some other imaging modalities, its specificity and sensitivity are exquisite [14] . Moreo-
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ver, quantitative analysis is relatively easy to accomplish with PET data. Therefore, several RGD peptide based PET tracers have been investigated for clinical translation including [ 18 Ga ]NOTA-PRGD2. In this review, we focus on these clinically available RGD-based PET tracers and intercompare them in terms of radiosynthesis, dosimetry, pharmacokinetics and clinical efficacy. We also noticed that several 99m In-labeled RGD peptide tracers have been used in clinical investigations. Due to the lack of direct comparison between SPECT and PET, these non-PET tracers are not included for discussion.
Radiosynthesis
For radionuclide imaging, strategies in radiotracer design and synthesis are required to decrease the barriers involved in radiochemistry and allow more researchers and clinicians to pursue preclinical investigation or clinical practice [15] . The RGD peptides have been successfully radiolabeled with 18 F and 68 Ga via different routes of chemistry and radiochemistry (Figure 1) . The radiolabeling stategies of these compounds are summarized in Table 1 .
[ 18 F]Galacto-RGD was the first RGD PET tracer tested in human subjects [16] . This compound was designed by conjugating a sugar amino acid to the cyclic peptide c(RGDfK) [17] . Radiolabeling of the glycopeptide was performed via acylation of the amino methyl group at the C1-position of the sugar moiety using 4-nitrophenyl-2-[ 18 F]fluoropropionate. The whole radiolabeling process requires 4 steps of radiosynthesis and 3 rounds of HPLC purification. Final HPLC with a semi-preparative column obtains [ 18 F]Galacto-RGD with specific activities ranging between 40 and 100 GBq/μmol and radiochemical purity over 98%. The total synthesis time was about 200 ± 18 min (including final HPLC purification) with radiochemical yield of 29.5 ± 5.1% (decay corrected). According to Beer et al. [18] [25, 36] *The radiolabeling procedures of several peptides were performed without HPLC purification (such as 18 F-Alfatide, 68 Ga-NOTA-RGD, 68 Ga-NOTA-PRGD2), and the specific activity is strongly dependent on the activity used for the synthesis.
[ [22] .
As shown, all these 18 F-labeled RGD peptides suffered from multistep, time-consuming and low-yield synthetic procedures. Moreover, it is very challenging to make these radiosynthetic processes fully automatic, which in turn sets a high technical barrier for using these PET probes in the clinical setting. Application of chelation chemistry has led to the discovery and development of [ 18 F]fluoridealuminum complexes to radiolabel peptides [23, 24] [25] . Under recently introduced kit formulation method, the total time can be reduced to 20 min, with a decay-corrected yield of 42.1 ± 2.0% and radiochemical purity of over 95% [26] . The specific activity of [ 18 F]Alfatide was calculated to be at least 37 GBq/μmol. However, the glutamic acid linked dimeric peptide with a free α-amine is not stable under acidic condition [27] , presumably due to the neighboring amine participation in the hydrolysis. Consequently, a much more stable new tracer [ 18 F]NOTA-E[PEG4-c(RGDfk)] 2 (denoted as Alfatide II) has been developed. Alfatide II can also be radiolabeled using the kit formulation method [28, 29] , which is pretty similar to Alfatide. The total synthesis time was about 20 min with radiochemical yield of 40-60% (corrected) and radiochemical purity > 95%. The specific activity was about 14.8-37 GBq/μmol at the end of synthesis based on the amount of peptide used and the amount of radioactivity trapped on the C 18 [30] reported labeling efficiency was around 90% (uncorrected) with the specific activity of 17.4 GBq/µmol (with HPLC purification). In a later report from the same group, [ 68 Ga]NOTA-RGD was synthesized using a minor modification for a clinical study (without HPLC purification) [31] . In this study, the compound could be produced with a reaction time of 5 min followed by Sep-Pak purification, yielding in >98% of the product with a specific activity of 74 GBq/umol. Regarding the dimeric RGD compound, the radiolabeling of [ 68 Ga]NOTA-PRGD2 was reported by Chen group. With HPLC purification, the radiochemical yield for [ 68 Ga]NOTA-PRGD2 was about 70% (uncorrected) with the specific activity around 9.4 GBq/µmol [25] . To further simplify the labeling procedure, the solid-phase extraction method was used to prepare [ 68 Ga]NOTA-PRGD2. Through this method, the radiochemical yield was 90% at 80 ºC with radiochemical purity over 95%. The specific activity ranges from 9.25-46.25 GBq/μmol at the end of synthesis based on the amount of peptide and radioactivity used. Table 2 based on existing clinical data. The biodistribution data showed primary renal route of tracer clearance, with prominent tracer uptake in the kidneys and bladder (Figure 2) . Concerning the intense tracer accumulation in the urine, image quality and analysis of lesions that adjacent to the urogenital tract and bladder are impaired. Therefore, before imaging, patients should be instructed to urinate to reduce the degree of tracer uptake in the bladder. Under certain circumstances, urinary catheter irrigation should be considered to lower the background signal. The RGD radioligand is retained in the tumor tissue for more than 60 min, whereas the background activity in the blood pool and muscle tissue is low and gradually decreased over time. For example, the blood and plasma clearance curves show that approximately 25% of [ 18 F]FPPRGD2 remains in the circulation at 30 min post-injection (p.i.), and less than 20% at 60 min [34] . Therefore, image acquisition at 40-60 min p.i. is recommended as earlier time point scans will have high nonspecific uptake which is likely to affect the image quality and ability to quantify integrin receptor level.
With such biodistribution patterns, RGD PET is well suited for detecting lesions in lungs, mediastinum, head-and-neck area, thorax including the breast, skeletal system and the extremities. Respecting tumors in the liver, spleen, and intestines, the detection efficiency may be unsatisfactory due to the relatively high background activity in these organs. For example, at 1 h after injection, [ 18 F]AH11185 shows normal liver uptake with a SUV mean of 3.7-4.6 [37] [38] . The relatively high physiological liver uptake usually makes it hard to identify liver metastases (SUVs from the liver lesions usually range from 1.4-3.9) [37] . On the other hand, RGD peptide is not able to cross the blood brain barrier (BBB), as tracer uptake in normal brain tissue is even lower than the tracer uptake in background tissue, like muscle [39] . In patients with high-grade glioma (grade III-IV), BBB is partially or completely disrupted, tumor/background ratios are normally remarkable within the area of brain [38, 40, 41] .
Regarding the stability of these clinically investigated RGD compounds, all of them were confirmed to be stable in vivo after intravenous injection. The radioligands were slowly metabolized to hydrophilic metabolites, with the mean percentage of intact tracer in blood at 120 min after injection ranging from 75-96% [18, 42, 43] .
Radiation Dosimetry
As the patient is exposed to high-energy γ-rays during the PET scan, knowing the potential risk from radiation exposure is essential in assessing the clinical utility of PET, and this should be quantified and understood so that risk-benefit ratios could be evaluated [44] . According to the literature, the effective dose from [ 18 F]FDG PET/CT, with a diagnostic CT and 370 MBq administered FDG dose, is up to 32.18 mSv [45] . However, the effective dose from PET scan is only 6-7 mSv (16-18 μSv/MBq), which means the radiation dose to patient from a PET scan is modest and most of the radiation comes from the CT scan.
The effective radiation dose for a 68 Ga-labeled radiotracers have shorter physical half-life than 18 F-labeled radiotracers, this difference is balanced in terms of the radiation dose by the initial kinetic energy of positrons emitted (E max =1899 keV for 68 Ga vs. 633 keV for 18 F).
The effective doses of all clinically tested RGD PET tracers range from 10-40 μSv/MBq ( Table 1) . This corresponds to the second risk category defined by 2007 International Commission on Radiological Protection (ICRP), which is greater than 1 mSv but not more than 20 mSv [47] . Overall, 18 F-labeled RGD peptides are safe PET tracers with dosimetry profiles comparable to [ 18 F]FDG. Moreover, because RGD-based compounds are mainly cleared out through the urinary tract, the effective dose could be further reduced by reducing the voiding interval. Under certain circumstances, diuretic agents may also be considered to lower the effective dose.
Clinical applications

Detection of malignant lesions and tumor staging
One of the applications of RGD PET in the clinic is for tumor detection and staging, as integrin α v β 3 is a well-established biomarker of neoangiogenesis. A wide variety of tumor types were evaluated in clinical studies, e.g. glioblastoma multiforme (GBM), squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), breast cancer, melanoma, sarcoma, renal cancer, rectal cancer etc., with decent tumor/background contrast ( Table 3) . For [ 18 F]Galacto-RGD, tracer accumulation in tumor lesions showed great heterogeneity, with mean SUVs ranged between the background level to a maximum of 10 [16] (Figure 3A) . Summarized from all the studies reported, the sensitivity of [ 18 F]Galacto-RGD PET for all lesions falls in the range of 59-92%. To be specific, the sensitivity for primary lesions range between 83% and 100%, however, the sensitivity for metastatic lymph nodes (LNs) was only 33-54% and was 46-78% for distant metastases [16, 33, 39, [48] [49] [50] [51] Figure 3B ). The sensitivity for all lesions ranged from 88-94% and was 71-88% for distant metastases [37, 52] . These data demonstrated that the monomeric peptide tracer [ 18 As a matter of fact, the in vivo biodistribution pattern of RGD affects the detection efficiency of lesions in different regions. The organs with moderate to intense RGD uptake are mostly located in the abdomen and pelvis area, such as the liver, spleen, intestines, kidneys and bladder, making the assessment of metastases rather difficult in these areas. As to the missed LNs or metastases located in the lung, mediastinum, and thorax (area with low background activity), most of reported studies did not obtain tissue samples from these lesions. Therefore, it remains a question mark whether the failure to depict these lesions is a result of technical problems (limited spatial resolution of a clinical PET scanner) or insufficient integrin expression in these lesions.
A To further improve binding affinity and tumor retention of RGD radioligands, multimeric RGD peptides were introduced [54] [55] [56] [57] [58] [59] . Multimerization results in increased tumor uptake, binding affinity and tumor retention, and thus, may enhance the performance of integrin imaging [60] [61] [62] . However, a higher absolute tumor uptake of multimeric tracers does not necessarily result in improved imaging quality [59] . Indeed, the consequent higher background signals from tetrameric and octameric RGD peptides gave way to the more favorable dimeric scaffold for developing RGD peptide tracers [63] .
[ 18 F]FPPRGD2 was the first dimeric RGD peptide tracer applied in the clinic for PET imaging [64] . In a clinical study with 8 breast cancer participants [65] , primary and metastatic lesions showed [ 18 F]FPPRGD2 uptake with SUVs of 2.4-9.4 (mean, 5.6 ± 2.8) and 2.5-9.7 (mean, 5.0 ± 2.3) at 60 min p.i. (Figure 4A) [22] . Interestingly, in the case of lobular breast cancer, there was obvious tracer uptake in primary lesion and in sub-centimeter biopsy-proven axillary lymph nodes and thoracic spine metastases, whereas these lesions were not detected by 18 F-FDG PET. Furthermore, three biopsy-proven inflammatory lymph nodes showed mild 18 Up to now, only a small number of clinical investigations of dimeric RGD peptides were reported, and the sensitivity/specificity between dimers and monomers was never compared in the same patients and will unlikely to be studied. Therefore, additional evaluation with large cohorts are needed to determine if multimeric strategy indeed provides a higher sensitivity and specificity for tumor detection and staging than the monomeric RGD compounds and [ 18 F]FDG.
Noninvasive quantification of tumor integrin α v β 3 expression
To provide quantitative analysis is one major characteristics of molecular imaging using biomarker specific imaging tracers [14] . High level of inter-and intra-individual variation in RGD uptake from tumor area was observed from clinical studies of RGD PET, indicating heterogeneous integrin αvβ3 expression in different tumor lesions. In patients with various types of tumors, parameters from RGD PET imaging such as SUVs or tumor to blood (T/B) ratios were proved to significantly correlate with the parameters from histological examination including intensity of immunohistochemical staining against integrin α v β 3 and microvessel density (MVD) [39, 48-50, 52, 67] . Moreover, immunohistochemistry has confirmed the lack of α v β 3 expression in RGD-negative tumors and normal tissue [48] . These findings highlight such noninvasive imaging techniques hold the potential for appropriate patient selection, especially for those who are going to receive anti-α v β 3 treatments. However, α v β 3 is not only expressed on neovasculature, but also on the surface of some tumor cells as well, particularly in melanoma, glioma, and renal cell carcinoma [68] . Therefore, it is important to keep in mind that RGD PET does not necessarily reflect angiogenesis in all tumor types because tumoral expression of integrin αvβ3 was not excluded. For example, tumor uptake of [ 18 F]FPRGD2 were compared with integrin α v β 3 expression and histological markers of angiogenesis in 27 renal cell carcinoma (RCC) patients. In the group of clear cell RCC (ccRCC), the [ 18 F]FPRGD2 PET signal correlated with integrin α v β 3 expression by tumor cells and IHC results confirmed high expression of α v β 3 on ccRCC cells, whereas in the papillary RCC (pRCC) group, the signal correlated with integrin α v β 3 level on tumor vessels [67] . These results demonstrated that RGD uptake reflects the expression of integrin α v β 3 in renal tumors but represents angiogenesis only when tumor cells do not express integrin α v β 3 .
Up to now, several different tumor types have been systematically examined regarding their α v β 3 expression patterns as shown by RGD PET. In patients with SCCHN, immunohistochemistry showed predominant α v β 3 expression on tumor vasculature but not on tumor cells, thus in SCCHN, RGD PET may be regarded as a surrogate marker of angiogenesis [49] . However, in malignant melanoma and ccRCC, it is not appropriate to use RGD PET to evaluate angiogenesis, because αvβ3 is also highly expressive on the surface of these tumor cells [52] . Consequently, the interpretation of RGD PET imaging strongly depends on the tumor type analyzed, which still needs further investigation.
Imaging αvβ3 expression with RGD PET has been advocated for lesion detection but is not consistent with [ 18 F]FDG PET. In one study which compared [ 18 F]Galacto-RGD with [ 18 F]FDG PET, no correlation between FDG and RGD PET parameter in 18 patients with NSCLC and various other tumors was found (r = 0.157) [53] . Similar results were reported in a recent study which compared 68 Ga-RGD and [ 18 F]FDG PET/CT in different types of breast cancers [69] . This finding may be explained by the different accumulation mechanisms of the two compounds since FDG reflects the distribution of glucose uptake and phosphorylation by tumor cells, but RGD binds to integrin αvβ3 expressed on the surface of tumor cells and activated endothelial cells. It is also interesting to note that bone metastases showed a tendency of high RGD uptake [66] , which corroborates with the observation that integrin α v β 3 is an indicator for bone metastases [70] . Therefore, [ 18 
Applications beyond oncology
Ischemic vascular diseases, including myocardial infarction (MI) and stroke, have been the leading causes of death and disability worldwide. Angiogenesis is considered an integral part of the repair process after ischemic injury and has been a major focus of cardiovascular and neurovascular research [71] . Integrin αvβ3 may be an important theranostic target associated with post-MI and post-stroke repair processes after ischemic injury [72] . In one investigation, a patient with myocardial infarction underwent [ 18 F]Galacto-RGD PET/CT scan two weeks after percutaneous coronary intervention [73] . Focal tracer retention was found in the infarcted area, which was defined by the extent of delayed enhancement from MRI and severely reduced myocardial blood flow from 13 N-ammonia PET/CT. This signal may suggest that myocardial healing was taking place within the infarcted area. More recently, [ 68 Ga]NOTA-PRGD2 PET/CT was employed to evaluate integrin α v β 3 -related repair in 23 post-MI and 16 post-stroke patients [74] . Patchy [ 68 Ga]NOTA-PRGD2 uptake was found to be located at or immediately around the ischemic regions in 20/23 MI patients and punctate multifocal uptake occurred in 8/16 stroke patients. Moreover, [ 68 Ga]NOTA-PRGD2 uptake related with the disease phase and severity, suggesting that RGD PET can provide valuable semi-quantitative information about post-MI and post-stroke repair. Thus, noninvasive RGD PET appears to be promising for assessing therapies aiming to stimulate angiogenesis in ischemic vascular diseases.
Moyamoya disease (MMD), a progressive occlusive disease of the distal internal carotid artery, is one of the most important causes of cerebral infarct in children [75] . The disease is the most common pediatric cerebral vascular disease that requires surgical intervention as it does not respond to any current medical treatment [76] . Indirect revascularization is the most widely used treatment for pediatric MMD [77] . Because angiogenesis and collateral vessel formation is the key mechanism in indirect revascularization surgery for MMD, and integrin αvβ3 is overexpressed on endothelial cells of newly formed vessels, the assessment of angiogenic activity by RGD PET might be beneficial for investigating the revascularization mechanism and evaluating the efficacy of treatment. 68 Ga-RGD PET was thus performed in pediatric MMD patients undergoing indirect revascularization surgery, to evaluate angiogenic activity and its correlation with treatment efficacy [78] . [ 68 Ga]RGD PET exhibited increased tracer uptake mainly around the bony flap including adjacent tissue such as galea, suggesting angiogenic activation in the acute post-infarct area. The author also demonstrated that angiogenic activity gradually decreased in a time-dependent manner and was estimated to normalize at approximately 6 months after surgery. Thus, the assessment of angiogenic activity using RGD PET is expected to be an effective tool for evaluating the efficacy of revascularization therapy in MMD patients.
Atherosclerosis is the major reason for most clinical cardiovascular events, and inflammation and intraplaque angiogenesis are important features of atherosclerotic plaque progression and vulnerability [79] [80] [81] . In atherosclerotic lesions, both macrophages and activated endothelial cells highly express integrin αvβ3 [82] . Therefore, imaging integrin α v β 3 expression may be helpful to predict future risk of plaque rupture and allow evaluating anti-atherosclerotic therapy response. In a study involving patients with high grade carotid stenosis, Beer et al. [83] have demonstrated the feasibility of [ 18 F]Galacto-RGD PET/CT to visualize atherosclerotic lesions and evaluate integrin α v β 3 expression in plaques. Focal [ 18 F]Galacto-RGD uptake can be visualized in atherosclerotic lesions, and the uptake significantly correlated with intraplaque α v β 3 expression, suggesting that visualization of integrin α v β 3 expression in human plaques is generally possible with PET imaging by using appropriate RGD tracers.
Rheumatoid arthritis (RA) is one of the most common rheumatic disorders. RGD peptide tracers hold the potential for diagnosing and therapy response monitoring in RA because synovial angiogenesis and pannus formation are major histopathological findings in patients with RA. One clinical study used [ 68 Ga]PRGD2 PET to evaluate synovial angiogenesis and monitor response to treatment in patients with active RA [84] . High levels of [ 68 Ga]PRGD2 accumulation were found in the involved joints and tendon sheaths and diffuse distribution in the lining of the synovium. Additionally, in patients with intense [ 18 F]FDG uptake in muscles caused by arthritic pain, [ 68 Ga]PRGD2 PET/CT was found to be better able to evaluate disease severity than [ 18 F]FDG PET/CT. Moreover, the change of [ 68 Ga]PRGD2 accumulation was found to be in response to therapeutic intervention, and the changes in [ 68 Ga]PRGD2 uptake significantly correlated with the changes in clinical disease activity index. From this study, RGD PET/CT appears to be an effective tool for identifying and assessing inflammatory synovial angiogenesis in RA patients.
Other perspective clinical applications
Patient risk stratification and patient selection for antiangiogenic therapy
Since integrin α v β 3 is an essential hallmark of tumor growth, invasion and metastasis, imaging integrin α v β 3 expression with PET is potentially interesting for patient risk stratification and patient selection for antiangiogenic therapy. In preclinical studies, expression of integrin α v β 3 has been reported to be associated with tumor aggressiveness and metastatic potential in malignant tumors [4] . For example, integrin α v β 3 plays an essential role in the progression of malignant melanoma, during the transition of cells from radial growth phase to the vertical growth phase [85] . [ 18 F]Galacto-RGD PET observed high variations of tumor uptake in melanoma patients [33] . For sarcoma and glioma, RGD uptake was positively correlated with the grade of tumor differentiation [40, 48] . Preclinical studies have also shown that expression level of integrin αvβ3 is associated with tumor aggressiveness and metastatic potential of breast cancer [86] , and integrin targeted therapy with Cilengitide showed promising results in breast cancer tumor-bearing mice [87] . Therefore, RGD PET may be effective for patient risk stratification. In addition, integrin αvβ3 imaging with RGD peptide tracers might also be useful in determining patient integrin status before starting therapies against the same target (such as Cilengitide). The current controversial findings and limited success especially in multicenter clinical trials with Cilengitide as monotherapy or as an adjuvant to the standard of care might suggest the importance of integrin imaging prior to patient recruitment. It is hopeful that companion integrin imaging and anti-integrin therapy, or integrin targeted theranostics, will likely have better outcomes. Patient stratification by integrin imaging will only enroll patients with medium to high integrin expression. Those patients with low levels of αvβ3 will be switched to alternative treatment regimens in the first place, avoiding ineffective treatment.
Therapy response monitoring
Although a good number of angiogenesis inhibitors are now being used in the clinic, it is also important to note that not all patients benefit from therapy with a specific antiangiogenic drug, and some tumors may become resistant to such therapy. As integrin αvβ3 is a key player in angiogenesis, it therefore can act as a predictive biomarker to select patients who will most likely benefit from a specific angiogenesis inhibitor, to evaluate treatment response, and to detect emerging resistance. Therefore, imaging integrin αvβ3 expression might be a useful method for early predicting antiangiogenic therapy response. This is particularly important as antiangiogenic therapy usually leads to a delay of tumor growth, rather than tumor shrinkage. As such, traditional imaging methods that only monitor morphologic changes will not be appropriate.
Currently, there are some preclinical studies on the use of RGD-based PET tracers for antiangiogenic therapy response monitoring. Unlike previous researches [88, 89] , these studies mostly focus on the tumor models in which integrin αvβ3 is mainly expressed on tumor vasculature, thus, the signal from RGD PET imaging only reflects α v β 3 expression on activated endothelial cells of the tumor vasculature. However, the results are still controversial. Some studies indicate that RGD PET is capable of measuring the changes of neovascular density and integrin expression during antiangiogenic therapy [90, 91] . However, other studies concluded that the tumor uptake of RGD peptide does not necessarily reflect changes of αvβ3 expression by intratumoral blood vessels early during the course of antiangiogenic therapy [92] . Thus, the efficacy of RGD PET imaging for tumor therapy monitoring relies heavily on the therapy protocol and tumor type analyzed.
Moreover, the findings regarding monitoring antiangiogenic therapies with RGD PET are confined to experimental animals. A well-defined clinical trial using αvβ3 imaging as a surrogate marker to assess response to antiangiogenic therapies is going to be the most important next step. This is difficult to carry out as many antiangiogenic drugs are now combined with chemotherapy, it is therefore not clear whether the change observed in the PET signals is due to the decreased angiogenesis or other factors like apoptosis or necrosis induced by chemotherapy. Hopefully, through imaging αvβ3 expression, we'll get a new tool at hand for guiding and tailoring antiangiogenic treatments to achieve individualized medicine.
Limitations of RGD compounds
As most RGD peptides have predominant renal clearance, this will impair detection of lesions in the urogenital tract. As such, tumors such as transitional cell carcinoma of bladder and urethra, localized prostate cancer and renal cancer are unlikely to be fully visualized by RGD PET. To a less extent this also applies to organs located in the abdominal area, such as spleen, liver and intestines. There is usually moderate to intense metabolic uptake in these organs (SUVs ranging from 2.5 to 4.0 at 1 h p.i.) [26, 33, 37, 65] .
Furthermore, as we have mentioned before, RGD PET does not necessarily allow specific visualization of angiogenesis in all tumor types because tumoral expression of integrin αvβ3 was not excluded. Thus, the interpretation of RGD PET is complex, and the potential of imaging integrin α v β 3 expression as a genuine biomarker of angiogenesis relies on the tumor type analyzed.
Another problem is the specificity of the signal obtained by RGD PET. This is because integrin α v β 3 can also be highly expressed on various of benign cells, such as smooth muscle cells, macrophages and osteoclasts. This has been confirmed by a number of clinical studies, e.g., myocardial infarction [93, 94] , atherosclerosis [83] , and cerebral infarct [95] . RGD-based compounds can also accumulate in some inflammatory lesions, such as cutaneous delayed-type hypersensitivity reaction [96] , villonodular synovitis [16] , hemangioma [53, 97] and oncocytoma [67] . This is because inflammatory lesions also involve neovasculature with activated endothelial cells which express integrin αvβ3. Therefore, like [ 18 F]FDG PET, RGD PET may not be able to differentiate inflammatory disease from malignant tumors effectively.
As for image quantification of RGD PET, the parameters from static PET scans, like SUV, %ID/g, are being widely used. However, besides the tracer binding affinity, the ability to convert tissue uptake into target concentration is unavoidably affected by other factors such as heterogeneity of blood supply, interstitial fluid pressure and vascular permeability. According to preclinical researches from Chen's group [98, 99] , dynamic RGD PET followed by the three compartment kinetic modeling can be used to discern specific integrin binding in tissue as it delineates specific uptake from the non-specific accumulation of RGD tracers in the tumor region. Moreover, parametric imaging from dynamic PET with RGD tracer demonstrates advantages in distinguishing effective from ineffective therapy early during vascular-disrupting [100] or chemotherapeutic [101] treatment. Therefore, quantitative analysis according to dynamic PET provides more sensitive evaluation than static PET. In one pilot clinical study with 18 lesions from 7 breast cancer patients, the kinetics of [ 18 F]fluciclatide has been established by using a two-tissue reversible binding model, the k 3 /k 4 ratio was found to be a reasonable measure of specific binding, which suggests that this index could be used for estimating α v β 3 expression in cancer lesions [102] . More recently, multi-bed-position dynamic imaging of [ 68 Ga]NOTA-PRGD2 was successfully performed in lung cancer patients [97] . Compared with static images, parametric maps showed substantial increase of tumor-background ratio and pixel-wise quantification of integrin expression in primary and metastatic lesions throughout the body. 
Conclusion
Great efforts have been made to develop radiolabeled RGD peptides for non-invasive determination of α v β 3 expression as well as monitoring tumor repsone to therapeutics involving angiogenesis. Ga ]NOTA-PRGD2 substantiated their advantages including easy preparation, fast labeling and superior in vivo pharmacokinetics than most of the existing monomeric RGD peptides. These tracers demonstrated the potential value of non-invasive techniques for patient risk stratification, patient selection for αvβ3-targeting therapies and monitoring of patients receiving such therapies. Therefore, to define the ultimate role of imaging α v β 3 expression in the clinic, large scale clinical trials using radiolabeled RGD tracers for therapy response assessment or patient prognosis evaluation are warranted.
